A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.

Since 1999, US states have tended to transition to more robust classes of prescription drug monitoring programs. Opioid overdose deaths in prior years predicted the state's prescription drug monitoring program class but did not predict transitions between prescription drug monitoring program classes over time.